Clinical Efficacy and Safety Evaluation of HCP1202 in COPD Patients

Chronic Obstructive Pulmonary Disease Clinical Trial

Official title:

A 24-week, Randomized, Double-Blind, Active-controlled, Parallel Study of HCP1202 Combination Product, HGP1011, and HCP0910 in Treatment of Subjects With COPD

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02941679
• Other study ID #: HM-FLUT-301
• Status: Not yet recruiting
• Phase: Phase 3
• First received: October 14, 2016
• Last updated: October 19, 2016
• Start date: October 2016
• Est. completion date: April 2018

Study information

• Verified date: October 2016
• Source: Hanmi Pharmaceutical Company Limited
• Contact: HyoungKyu Yoon, M.D., Ph.D.
• Email: cmcyhg[@]catholic.ac.kr
• Is FDA regulated: No
• Health authority: Korea: Ministry of Food and Drug Safety
• Study type: Interventional

Clinical Trial Summary

A phase 3 study to evaluate efficacy and safety of HCP1202

Description:

This study is designed as a multi-center, double-blinded, randomized, phase 3 clinical trial to evaluate the efficacy and safety of HCP1202 compared to either treatment with HGP1011 or HCP0910 in COPD patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 252
• Est. completion date: April 2018
• Est. primary completion date: February 2018
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Male or Female adults aged = 40 years.

• Patients diagnosed with COPD.

• Patients with FEV1/FVC < 0.7 at screening.

• Patients with a post-bronchodilator FEV1 < 60% of the predicted normal OR Patients with a post-bronchodilator FEV1 < 80% of the predicted normal if COPD exacerbation is moderate or worse developed at least twice within the past year or hospitalization occurred at least once within the past year due to COPD exacerbation.

• Patients with COPD Assessment Test = 10.

• Patients with a history (current or ex-smokers) of smoking 10 pack-years or more (e.g. 10 pack years = 1 pack/day x 10 years, or ½ pack/day x 20 years).

• Patients who understand the process of clinical trial and signed written informed consent.

Exclusion Criteria:

• Patients with a current diagnosis of asthma.

• Patients with the following lung disorders that can affect the clinical trial, except for COPD: lung cancer, interstitial lung disease, thromboembolic pulmonary disease, moderate to severe bronchiectasis, sarcoidosis, pulmonary fibrosis, pulmonary hypertension, active tuberculosis, clinically significant tuberculous destroyed lung, alpha1-antitrypsin deficiency, etc.

• Patients underwent pulmonary lobectomy or lung volume reduction surgery within the past year.

• Patients who developed COPD exacerbation where antibiotics and/or systemic corticosteroids and/or hospitalization is advisable within 4 weeks prior to Visit 1 or during Run-in period (but, re-screening is possible 4 weeks after resolution of the COPD exacerbation occurred within 4 weeks prior to Visit 1).

• Patients who administered antibiotics for lower respiratory infection within 4 weeks prior to Visit 1 or during Run-in period (but, re-screening is possible 4 weeks after resolution of COPD exacerbation occurred within 4 weeks prior to Visit 1).

• Patients who have changed the COPD treatment method within 12 weeks prior to Visit 1 (but, PDE4 inhibitor can be used until 4 weeks prior to Visit 1).

• Patients administered systemic corticosteroids within 4 weeks prior to Visit 1.

• Patients with the following clinically significant cardiovascular diseases: a history of myocardial infarction or unstable angina within 6 months prior to Visit 1, a history of unstable arrhythmia where its therapy method has been changed within 1 year prior to Visit 1, a history of hospitalization from NYHA Class III-IV heart failure, a history of atrial fibrillation, negative cardiac tachycardia, and/or hypertrophic cardiomyopathy.

• Patients with a history of long QTc syndrome.

• Patients with the clinical significance of ECG abnormality at screening (QTc(F) = 470 ms).

• Patients who require long-term oxygen therapy for more than 12 hours a day.

• Patients participated in acute respiratory rehabilitation within 6 months prior to Visit 1 (except for the patients under stabilized respiratory rehabilitation therapy of at least 6 weeks).

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• HCP1202
Hanmi Pharmaceutical. Co., Ltd.
• HGP1011
Boehringer Ingelheim
• HCP0910
GlaxoSmithKline

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Hanmi Pharmaceutical Company Limited

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in Trough FEV1 at Week 12		Baseline, Week 12	No
Secondary	Change from Baseline in Trough FEV1 at Week 4 & 8		Baseline, Week 4, Week 8	No
Secondary	Change from Baseline in Trough FVC at Week 4 & 8 & 12		Baseline, Week 4, Week 8, Week 12	No
Secondary	Change from Baseline in Trough FEV1/FVC at Week 4 & 8 & 12		Baseline, Week 4, Week 8, Week 12	No
Secondary	Transition Dyspnea Index scores at Week 4 & 8 & 12		Week 4, Week 8, Week 12	No
Secondary	Change from Baseline in Total SGRQ-C (St. George's Respiratory Questionnaire for COPD patients) and sectional scores at Week 4 & 8 & 12		Baseline, Week 4, Week 8, Week 12	No
Secondary	Percentage (%) of Subjects Experienced with Moderate to Severe COPD Exacerbation from Baseline to Week 12		Baseline through Week 12	Yes
Secondary	Number of Occurrences in Moderate to Severe COPD Exacerbation per Subject from Baseline to Week 12		Baseline through Week 12	Yes
Secondary	Total Amount of Rescue Medication Used per Subject from Baseline to Week 12		Baseline through Week 12	Yes
Secondary	Average Daily Use of Rescue Medication per Subject from Baseline to Week 12		Baseline through Week 12	Yes